Nanexa AB (FRA:40M) Beta: 1.6805 (As of Jun. 26, 2026)


FRA:40M Nanexa AB FRA:40M
48 GF Score
Price €0.31
GF Value €0.17
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Nanexa AB Beta?

Nanexa AB FRA:40M +5.06% 48 Beta is 1.6805 as of Jun. 26, 2026. GuruFocus rates FRA:40M with a GF Score™ of 48/100 and a GF Value™ of €0.17 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Nanexa AB's Beta is 1.6805.


Nanexa AB  (FRA:40M) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Nanexa AB Beta Related Terms


Nanexa AB Beta Historical Data

* Premium members only.

The historical data trend for Nanexa AB's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanexa AB Beta Chart

Nanexa AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.21 1.67

Nanexa AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.57 2.61 2.76 1.67 2.14

FRA:40M vs ZTS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nanexa AB's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanexa AB Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanexa AB's Beta distribution charts can be found below:

* The bar in red indicates where Nanexa AB's Beta falls into.


FRA:40M
48GF Score
Nanexa AB FRA:40M
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanexa AB Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.6805 mean?
Nanexa AB (FRA:40M) has a Beta of 1.6805 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Nanexa AB and its competitors.
Is Nanexa AB's Beta too high?
Nanexa AB's current Beta is 1.6805. Overall, Nanexa AB has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nanexa AB's Beta compare to ZTS?
Nanexa AB's Beta of 1.6805 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Nanexa AB and its competitors. Nanexa AB's current Beta is 1.6805. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanexa AB stock overvalued right now?
Based on GuruFocus' analysis, Nanexa AB (FRA:40M) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.17, compared to a current price of €0.31 — trading 83.2% above its estimated fair value. The current Beta is 1.6805. Nanexa AB's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Nanexa AB (FRA:40M), the current Beta is 1.6805 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanexa AB (FRA:40M) Overvalued in 2026?

Based on GuruFocus' analysis, Nanexa AB stock appears to be overvalued. The current stock price of €0.31 is trading 83.2% above its estimated GF Value™ of €0.17. GuruFocus considers Nanexa AB to be Significantly Overvalued.

Key valuation signals for FRA:40M:

  • Beta: 1.6805
  • GF Value™: €0.17 vs. price of €0.31 (83.2% above fair value)
  • GF Score™: 48/100 with 2 warning signs

No single metric tells the full story. See the FRA:40M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nanexa AB Business Description

Other Exchanges NANEXA:Sweden
Address Virdings Alle 32B, Uppsala, SWE, 75450
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries, while it also has its presence in Europe (excluding the Nordic countries), North America, and Asia.
48GF Score

Get the complete analysis for FRA:40M

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.31
Price
€0.17
GF Value